Literature DB >> 29997957

Lung function in the late postoperative phase and influencing factors in patients undergoing pulmonary lobectomy.

Ryoichi Matsumoto1, Shinzo Takamori1, Shintaro Yokoyama1, Toshihiro Hashiguchi1, Daigo Murakami1, Koichi Yoshiyama1, Tatsuya Nishi1, Masaki Kashihara1, Masahiro Mitsuoka1, Ryozo Hayashida2, Tatsuyuki Kakuma3, Yoshito Akagi1.   

Abstract

BACKGROUND: Lung function in the late postoperative phase after pulmonary lobectomy is insufficiently characterized. This study aimed to appraise lung function in the late postoperative phase according to vital capacity (VC) and forced expiratory volume in 1 second (FEV1) in patients who underwent pulmonary lobectomy.
METHODS: Pre- and postoperative VC and FEV1 were reviewed in 112 patients who underwent pulmonary lobectomy. Postoperative lung volume was assessed >1 year after surgery. Postoperative decreases in VC and FEV1 were compared with preoperative predicted values among patients who underwent resection of specific lobe. Determinants effecting a decrease in lung function were also investigated.
RESULTS: A mean postoperative decreased VC of 10.5%±1.8% was recorded in patients who underwent right upper lobectomy (RU), 7.2%±1.5% for right middle lobectomy (RM), 14.3%±2.3% for right lower lobectomy (RL), 16.6%±3.0% for left upper lobectomy (LU), and 14.7%±2.5% for left lower lobectomy (LL). Corresponding FEV1 values were 14.8%±1.8% for RU, 11.9%±4.0% for RM, 14.9%±2.3% for RL, 17.9%±2.9% for LU, and 15.1%±2.4% for LL. The actual decreasing rate of VC was overestimated in patients who underwent RU, RL, LU, and LL. In contrast, FEV1 was overestimated only in patients who underwent RL and LL. Patients with chronic obstructive pulmonary disease (COPD) exhibited significantly better preservation of FEV1.
CONCLUSIONS: Patients scheduled for RL and LL, or those with COPD, appeared to exhibit preserved lung function in the late postoperative phase after pulmonary lobectomy.

Entities:  

Keywords:  Pulmonary lobectomy; decreasing rate; forced expiratory volume in 1 second (FEV1); lung function; vital capacity (VC)

Year:  2018        PMID: 29997957      PMCID: PMC6006118          DOI: 10.21037/jtd.2018.05.27

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  24 in total

1.  ATS/ERS Statement on respiratory muscle testing.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-08-15       Impact factor: 21.405

2.  The effect of bronchitis, smoking, and occupation on ventilation.

Authors:  G L BRINKMAN; E O COATES
Journal:  Am Rev Respir Dis       Date:  1963-05

3.  Regional lung growth following pneumonectomy assessed by computed tomography.

Authors:  Priya Ravikumar; Cuneyt Yilmaz; D Merrill Dane; Robert L Johnson; Aaron S Estrera; Connie C W Hsia
Journal:  J Appl Physiol (1985)       Date:  2004-06-18

4.  Does lobectomy for lung cancer in patients with chronic obstructive pulmonary disease affect lung function? A multicenter national study.

Authors:  Sergio Baldi; Enrico Ruffini; Sergio Harari; Gian Carlo Roviaro; Mario Nosotti; Nadia Bellaviti; Federico Venuta; Daniele Diso; Federico Rea; Claudio Schiraldi; Alberto Durigato; Maurizio Pavanello; Angelo Carretta; Piero Zannini
Journal:  J Thorac Cardiovasc Surg       Date:  2005-12       Impact factor: 5.209

5.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.

Authors:  R J Ginsberg; L V Rubinstein
Journal:  Ann Thorac Surg       Date:  1995-09       Impact factor: 4.330

6.  Recovery and limitation of exercise capacity after lung resection for lung cancer.

Authors:  K Nezu; K Kushibe; T Tojo; M Takahama; S Kitamura
Journal:  Chest       Date:  1998-06       Impact factor: 9.410

7.  Pulmonary function and exercise capacity after lung resection.

Authors:  C T Bolliger; P Jordan; M Solèr; P Stulz; M Tamm; C Wyser; M Gonon; A P Perruchoud
Journal:  Eur Respir J       Date:  1996-03       Impact factor: 16.671

8.  Prediction of ventilatory capacity after lobectomy.

Authors:  S Kristersson; M Arborelius; G Jungquist; B Lilja; L Svanberg
Journal:  Scand J Respir Dis       Date:  1973

9.  Lobar volume reduction surgery: a method of increasing the lung cancer resection rate in patients with emphysema.

Authors:  J G Edwards; D J Duthie; D A Waller
Journal:  Thorax       Date:  2001-10       Impact factor: 9.139

10.  Minimal alteration of pulmonary function after lobectomy in lung cancer patients with chronic obstructive pulmonary disease.

Authors:  Yasuo Sekine; Takekazu Iwata; Masako Chiyo; Kazuhiro Yasufuku; Shinichiro Motohashi; Shigetoshi Yoshida; Makoto Suzuki; Toshihiko Iizasa; Yukio Saitoh; Takehiko Fujisawa
Journal:  Ann Thorac Surg       Date:  2003-08       Impact factor: 4.330

View more
  4 in total

Review 1.  Quality of Life After Stereotactic Body Radiation therapy Versus Video-Assisted Thoracic Surgery in Early stage Non-small Cell Lung Cancer. Is there Enough Data to Make a Recommendation?

Authors:  O Leaman-Alcibar; C Cigarral; C Déniz; I Romero-Palomar; A Navarro-Martin
Journal:  J Clin Transl Res       Date:  2021-04-22

2.  Measured versus predicted postoperative pulmonary function at repeated times up to 1 year after lobectomy.

Authors:  Takamasa Shibazaki; Shohei Mori; Eriko Harada; Rintaro Shigemori; Daiki Kato; Hideki Matsudaira; Jun Hirano; Takashi Ohtsuka
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-10-29

3.  A preliminary study identifies early postoperative lung volume changes in patients with non-small cell lung cancer following video-assisted thoracic surgery using CT volumetry.

Authors:  Xiaojun Du; Haojun Li; Langbo Liu; Min Zhang; Zhongben Tang; Jian Zhang; Peng Lin; Hong Xie; Cheng Chen
Journal:  Mol Clin Oncol       Date:  2021-04-22

Review 4.  Rapid Recovery of Postoperative Pulmonary Function in Patients With Lung Cancer and Influencing Factors.

Authors:  Yang Fuzhi; Tang Dongfang; Fu Wentao; Wang Jing; Wu Yingting; Mo Nianping; Gao Wen; Shen Xiaoyong
Journal:  Front Oncol       Date:  2022-07-11       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.